Post-op CXL pain linked to age

Article

Collagen cross-linking (CXL) can cause more intense postoperative pain in younger patients.

Collagen cross-linking (CXL) can cause more intense postoperative pain in younger patients, according to a paper published in Cornea.

Dr Vinícius Ghanem et al., Cornea Department, Sadalla Amin Ghanem Eye Hospital, Joinville, Brazil, conducted a prospective study on 178 consecutive eyes of 135 patients with progressive keratoconus who underwent CXL.

The need for analgaesia with 30 mg of codeine and subjective self-evaluation was used to assess postoperative pain. Subjective evaluation was completed using the Wong-Baker FACES Pain Rating Scale at the end of each postoperative (PO) day for five days. The correlation between postoperative pain/keratometric readings and central corneal thickness (CCT) was assessed preoperatively.

The results revealed the mean number of codeine pills administered was 0.94, 0.72 and 0.28 at iPO, PO1 and PO2, respectively. There was a significant link between age and pain at PO3 and PO4 and between age and number of codeine pills on iPO. However, there was no significant association between mean overall pain and preoperative apical keratometry and pachymetry readings.

After CXL, pain is especially intense in particular during the first three postoperative days, despite aggressive pain control regimens. However, on each consecutive day, pain and the need for analgaesia decreased significantly.

The abstract can be viewed here.

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.